The impacts of Medicare biosimilar reimbursement policies.

View Full Paper

Ask AI

Bookmark

Biosimilar reimbursement rates fluctuated following the introduction of the Inflation Reduction Act, diverging from previous models.
Over 73% of biosimilar MCRs surpassed their ASP+6% threshold before and during the IRA period, indicating pricing challenges.
A retrospective analysis of MCR and ASP data for nine reference biologics and over 30 biosimilars was conducted from 2018-2025.
The study suggests that policy misalignments may complicate biosimilar adoption and competition in the biologics market.

Discussion

No takes yet. Share an insight, caveat, or question.

Retrospective analysis evaluates biosimilar pricing changes from Medicare reimbursement policies, highlighting implications for market competition.

Indurlal et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective analysis evaluates biosimilar pricing changes from Medicare reimbursement policies, highlighting implications for market competition.